BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34-44. [PMID: 28442273 DOI: 10.1016/j.mam.2017.04.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 62] [Article Influence: 10.6] [Reference Citation Analysis]
Number Citing Articles
1 Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
2 Yan M, Man S, Ma L, Gao W. Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. Metabolism 2022;134:155264. [PMID: 35810782 DOI: 10.1016/j.metabol.2022.155264] [Reference Citation Analysis]
3 Garcia CJ, Kosek V, Beltrán D, Tomás-barberán FA, Hajslova J. Production of New Microbially Conjugated Bile Acids by Human Gut Microbiota. Biomolecules 2022;12:687. [DOI: 10.3390/biom12050687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Dong Z, Yang X, Qiu T, an Y, Zhang G, Li Q, Jiang L, Yang G, Cao J, Sun X, Liu X, Liu D, Yao X. Exosomal miR-181a-2-3p derived from citreoviridin-treated hepatocytes activates hepatic stellate cells trough inducing mitochondrial calcium overload. Chemico-Biological Interactions 2022. [DOI: 10.1016/j.cbi.2022.109899] [Reference Citation Analysis]
5 Puengel T, Liu H, Guillot A, Heymann F, Tacke F, Peiseler M. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:2668. [PMID: 35269812 DOI: 10.3390/ijms23052668] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
6 Shen R, Ke L, Li Q, Dang X, Shen S, Shen J, Li S, Liang L, Peng B, Kuang M, Ma Y, Yang Z, Hua Y. Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma. Hepatol Int 2022. [PMID: 35211843 DOI: 10.1007/s12072-022-10299-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dong Z, He F, Yan X, Xing Y, Lei Y, Gao J, He M, Li D, Bai L, Yuan Z, Y-J Shyy J. Hepatic Reduction in Cholesterol 25-Hydroxylase Aggravates Diet-Induced Steatosis. Cell Mol Gastroenterol Hepatol 2022:S2352-345X(21)00271-X. [PMID: 34990887 DOI: 10.1016/j.jcmgh.2021.12.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Shao Q, Wu Y, Ji J, Xu T, Yu Q, Ma C, Liao X, Cheng F, Wang X. Interaction Mechanisms Between Major Depressive Disorder and Non-alcoholic Fatty Liver Disease. Front Psychiatry 2021;12:711835. [PMID: 34966296 DOI: 10.3389/fpsyt.2021.711835] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Hou JJ, Wang X, Wang YM, Wang BM. Interplay between gut microbiota and bile acids in diarrhoea-predominant irritable bowel syndrome: a review. Crit Rev Microbiol 2021;:1-18. [PMID: 34936854 DOI: 10.1080/1040841X.2021.2018401] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Zhu C, Huang M, Kim HG, Chowdhury K, Gao J, Liu S, Wan J, Wei L, Dong XC. SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1. Biochim Biophys Acta Mol Basis Dis 2021;1867:166249. [PMID: 34425214 DOI: 10.1016/j.bbadis.2021.166249] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Roberts SK, Majeed A. A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Ther Targets 2021;25:889-95. [PMID: 34727818 DOI: 10.1080/14728222.2021.1999416] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Ji Y, Lee H, Kaura S, Yip J, Sun H, Guan L, Han W, Ding Y. Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms. Biomolecules 2021;11:1582. [PMID: 34827579 DOI: 10.3390/biom11111582] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Yang C, Wan M, Xu D, Pan D, Xia H, Yang L, Sun G. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis. Int J Mol Sci 2021;22:10858. [PMID: 34639207 DOI: 10.3390/ijms221910858] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 Cheng H, Liu J, Tan Y, Feng W, Peng C. Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine. Journal of Pharmaceutical Analysis 2021. [DOI: 10.1016/j.jpha.2021.10.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
16 Jayasuriya R, Dhamodharan U, Ali D, Ganesan K, Xu B, Ramkumar KM. Targeting Nrf2/Keap1 signaling pathway by bioactive natural agents: Possible therapeutic strategy to combat liver disease. Phytomedicine 2021;92:153755. [PMID: 34583226 DOI: 10.1016/j.phymed.2021.153755] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
17 Du JJ, Sun JC, Li N, Li XQ, Sun WY, Wei W. β-Arrestin2 deficiency attenuates oxidative stress in mouse hepatic fibrosis through modulation of NOX4. Acta Pharmacol Sin 2021;42:1090-100. [PMID: 33116250 DOI: 10.1038/s41401-020-00545-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
18 Jiang L, Schnabl B. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know? Physiology (Bethesda) 2020;35:261-74. [PMID: 32490750 DOI: 10.1152/physiol.00005.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
19 Li D, Cui Y, Wang X, Liu F, Li X. Apple Polyphenol Extract Improves High-Fat Diet-Induced Hepatic Steatosis by Regulating Bile Acid Synthesis and Gut Microbiota in C57BL/6 Male Mice. J Agric Food Chem 2021;69:6829-41. [PMID: 34124904 DOI: 10.1021/acs.jafc.1c02532] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
20 Xiong F, Zheng Z, Xiao L, Su C, Chen J, Gu X, Tang J, Zhao Y, Luo H, Zha L. Soyasaponin A2 Alleviates Steatohepatitis Possibly through Regulating Bile Acids and Gut Microbiota in the Methionine and Choline-Deficient (MCD) Diet-induced Nonalcoholic Steatohepatitis (NASH) Mice. Mol Nutr Food Res 2021;65:e2100067. [PMID: 34047448 DOI: 10.1002/mnfr.202100067] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
21 Wu T, Yang M, Xu H, Wang L, Wei H, Ji G. Serum Bile Acid Profiles Improve Clinical Prediction of Nonalcoholic Fatty Liver in T2DM patients. J Proteome Res 2021;20:3814-25. [PMID: 34043368 DOI: 10.1021/acs.jproteome.1c00104] [Reference Citation Analysis]
22 Li C, Zhou W, Li M, Shu X, Zhang L, Ji G. Salvia-Nelumbinis naturalis extract protects mice against MCD diet-induced steatohepatitis via activation of colonic FXR-FGF15 pathway. Biomed Pharmacother 2021;139:111587. [PMID: 33865013 DOI: 10.1016/j.biopha.2021.111587] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
23 Huang W, Kong D. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. Biomedicine & Pharmacotherapy 2021;135:111235. [DOI: 10.1016/j.biopha.2021.111235] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
24 Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. Int J Biol Sci 2021;17:818-33. [PMID: 33767591 DOI: 10.7150/ijbs.56214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
25 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
26 Jia W, Rajani C, Xu H, Zheng X. Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma. Protein Cell 2021;12:374-93. [PMID: 32797354 DOI: 10.1007/s13238-020-00748-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
27 Albhaisi S, Sanyal AJ. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceut Med 2019;33:451-63. [PMID: 31933238 DOI: 10.1007/s40290-019-00305-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
28 Fang M, Zhang Q, Yu P, Ge C, Guo J, Zhang Y, Wang H. The effects, underlying mechanism and interactions of dexamethasone exposure during pregnancy on maternal bile acid metabolism. Toxicol Lett 2020;332:97-106. [PMID: 32599024 DOI: 10.1016/j.toxlet.2020.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ladurner A, Linder T, Wang L, Hiebl V, Schuster D, Schnürch M, Mihovilovic MD, Atanasov AG, Dirsch VM. Characterization of a Structural Leoligin Analog as Farnesoid X Receptor Agonist and Modulator of Cholesterol Transport. Planta Med 2020;86:1097-107. [PMID: 32485752 DOI: 10.1055/a-1171-8357] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Sun HJ, Wu ZY, Nie XW, Wang XY, Bian JS. Implications of hydrogen sulfide in liver pathophysiology: Mechanistic insights and therapeutic potential. J Adv Res 2021;27:127-35. [PMID: 33318872 DOI: 10.1016/j.jare.2020.05.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
31 Li Q, Li M, Li F, Zhou W, Dang Y, Zhang L, Ji G. Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice. J Ethnopharmacol 2020;258:112896. [PMID: 32325178 DOI: 10.1016/j.jep.2020.112896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
32 Yamamoto S, Sato I, Fukuhama N, Akiyama N, Sakai M, Kumazaki S, Ran S, Hirohata S, Kitamori K, Yamori Y, Watanabe S. Bile acids aggravate nonalcoholic steatohepatitis and cardiovascular disease in SHRSP5/Dmcr rat model. Exp Mol Pathol 2020;114:104437. [PMID: 32246926 DOI: 10.1016/j.yexmp.2020.104437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Fujihira H, Masahara-negishi Y, Akimoto Y, Hirayama H, Lee H, Story BA, Mueller WF, Jakob P, Clauder-münster S, Steinmetz LM, Radhakrishnan SK, Kawakami H, Kamada Y, Miyoshi E, Yokomizo T, Suzuki T. Liver-specific deletion of Ngly1 causes abnormal nuclear morphology and lipid metabolism under food stress. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2020;1866:165588. [DOI: 10.1016/j.bbadis.2019.165588] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
34 Fitzgerald BL, Molins CR, Islam MN, Graham B, Hove PR, Wormser GP, Hu L, Ashton LV, Belisle JT. Host Metabolic Response in Early Lyme Disease. J Proteome Res 2020;19:610-23. [PMID: 31821002 DOI: 10.1021/acs.jproteome.9b00470] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
35 Segovia-Miranda F, Morales-Navarrete H, Kücken M, Moser V, Seifert S, Repnik U, Rost F, Brosch M, Hendricks A, Hinz S, Röcken C, Lütjohann D, Kalaidzidis Y, Schafmayer C, Brusch L, Hampe J, Zerial M. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat Med 2019;25:1885-93. [PMID: 31792455 DOI: 10.1038/s41591-019-0660-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 7.7] [Reference Citation Analysis]
36 Luan Z, Huo X, Dong P, Tian X, Sun C, Lv X, Feng L, Ning J, Wang C, Zhang B, Ma X. Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism. European Journal of Medicinal Chemistry 2019;182:111652. [DOI: 10.1016/j.ejmech.2019.111652] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
37 Li D, Liu F, Wang X, Li X. Apple Polyphenol Extract Alleviates High-Fat-Diet-Induced Hepatic Steatosis in Male C57BL/6 Mice by Targeting LKB1/AMPK Pathway. J Agric Food Chem 2019;67:12208-18. [DOI: 10.1021/acs.jafc.9b05495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
38 Liu Q, Niu CY. From "two hit theory" to "multiple hit theory": Implications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2019; 27(19): 1171-1178 [DOI: 10.11569/wcjd.v27.i19.1171] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Sundaram S, Palaniappan B, Nepal N, Chaffins S, Sundaram U, Arthur S. Mechanism of Dyslipidemia in Obesity-Unique Regulation of Ileal Villus Cell Brush Border Membrane Sodium-Bile Acid Cotransport. Cells 2019;8:E1197. [PMID: 31623375 DOI: 10.3390/cells8101197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
40 Krishnan S, Ding Y, Saedi N, Choi M, Sridharan GV, Sherr DH, Yarmush ML, Alaniz RC, Jayaraman A, Lee K. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. Cell Rep. 2018;23:1099-1111. [PMID: 29694888 DOI: 10.1016/j.celrep.2018.03.109] [Cited by in Crossref: 160] [Cited by in F6Publishing: 220] [Article Influence: 53.3] [Reference Citation Analysis]
41 Ji Y, Yin Y, Li Z, Zhang W. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients. 2019;11. [PMID: 31349604 DOI: 10.3390/nu11081712] [Cited by in Crossref: 31] [Cited by in F6Publishing: 61] [Article Influence: 10.3] [Reference Citation Analysis]
42 Liu Q, Liu S, Chen L, Zhao Z, Du S, Dong Q, Xin Y, Xuan S. Role and effective therapeutic target of gut microbiota in NAFLD/NASH. Exp Ther Med 2019;18:1935-44. [PMID: 31410156 DOI: 10.3892/etm.2019.7781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
43 Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349-364. [PMID: 29740166 DOI: 10.1038/s41575-018-0009-6] [Cited by in Crossref: 303] [Cited by in F6Publishing: 286] [Article Influence: 101.0] [Reference Citation Analysis]
44 Suga T, Yamaguchi H, Ogura J, Shoji S, Maekawa M, Mano N. Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis. Toxicol Appl Pharmacol 2019;379:114664. [PMID: 31306673 DOI: 10.1016/j.taap.2019.114664] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
45 Zhang Y, Jiang R, Zheng X, Lei S, Huang F, Xie G, Kwee S, Yu H, Farrar C, Sun B, Zhao A, Jia W. Ursodeoxycholic acid accelerates bile acid enterohepatic circulation. Br J Pharmacol 2019;176:2848-63. [PMID: 31077342 DOI: 10.1111/bph.14705] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
46 Lin S, Wang T, Xu H, Zhang X, Wang Q, Liu R, Li Q, Bi K. A systemic combined nontargeted and targeted LC-MS based metabolomic strategy of plasma and liver on pathology exploration of alpha-naphthylisothiocyanate induced cholestatic liver injury in mice. Journal of Pharmaceutical and Biomedical Analysis 2019;171:180-92. [DOI: 10.1016/j.jpba.2019.04.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
47 Rizzolo D, Buckley K, Kong B, Zhan L, Shen J, Stofan M, Brinker A, Goedken M, Buckley B, Guo GL. Bile Acid Homeostasis in a Cholesterol 7α-Hydroxylase and Sterol 27-Hydroxylase Double Knockout Mouse Model. Hepatology 2019;70:389-402. [PMID: 30864232 DOI: 10.1002/hep.30612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
48 Zhang F, Yuan W, Wei Y, Zhang D, Duan Y, Li B, Wang X, Xi L, Zhou Y, Wu X. The alterations of bile acids in rats with high-fat diet/streptozotocin-induced type 2 diabetes and their negative effects on glucose metabolism. Life Sciences 2019;229:80-92. [DOI: 10.1016/j.lfs.2019.05.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
49 Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Mediators Inflamm. 2019;2019:7659509. [PMID: 31341422 DOI: 10.1155/2019/7659509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
50 Hong W, Li S, Wu L, He B, Jiang J, Chen Z. Prediction of VEGF-C as a Key Target of Pure Total Flavonoids From Citrus Against NAFLD in Mice via Network Pharmacology. Front Pharmacol 2019;10:582. [PMID: 31214028 DOI: 10.3389/fphar.2019.00582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
51 Sánchez-crisóstomo I, Fernández-martínez E, Cariño-cortés R, Betanzos-cabrera G, Bobadilla-lugo RA. Phytosterols and Triterpenoids for Prevention and Treatment of Metabolic-related Liver Diseases and Hepatocellular Carcinoma. CPB 2019;20:197-214. [DOI: 10.2174/1389201020666190219122357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
52 Guo GL, Xie W. Metformin action through the microbiome and bile acids. Nat Med 2018;24:1789-90. [PMID: 30523325 DOI: 10.1038/s41591-018-0273-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
53 Hu J, Hong W, Yao KN, Zhu XH, Chen ZY, Ye L. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway. World J Gastroenterol 2019; 25(12): 1492-1501 [PMID: 30948912 DOI: 10.3748/wjg.v25.i12.1492] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
54 Xu Y, Han J, Dong J, Fan X, Cai Y, Li J, Wang T, Zhou J, Shang J. Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development. Int J Mol Sci 2019;20:E1220. [PMID: 30862046 DOI: 10.3390/ijms20051220] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
55 Kong B, Zhang M, Huang M, Rizzolo D, Armstrong LE, Schumacher JD, Chow MD, Lee YH, Guo GL. FXR deficiency alters bile acid pool composition and exacerbates chronic alcohol induced liver injury. Dig Liver Dis 2019;51:570-6. [PMID: 30803859 DOI: 10.1016/j.dld.2018.12.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
56 Khonche A, Huseini HF, Gholamian M, Mohtashami R, Nabati F, Kianbakht S. Standardized Nigella sativa seed oil ameliorates hepatic steatosis, aminotransferase and lipid levels in non-alcoholic fatty liver disease: A randomized, double-blind and placebo-controlled clinical trial. J Ethnopharmacol 2019;234:106-11. [PMID: 30639231 DOI: 10.1016/j.jep.2019.01.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
57 Massafra V, Pellicciari R, Gioiello A, van Mil SW. Progress and challenges of selective Farnesoid X Receptor modulation. Pharmacology & Therapeutics 2018;191:162-77. [DOI: 10.1016/j.pharmthera.2018.06.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
58 Zhang F, Xi L, Duan Y, Qin H, Wei M, Wu Y, Li B, Zhou Y, Wu X. The ileum-liver Farnesoid X Receptor signaling axis mediates the compensatory mechanism of 17α-ethynylestradiol-induced cholestasis via increasing hepatic biosynthesis of chenodeoxycholic acids in rats. European Journal of Pharmaceutical Sciences 2018;123:404-15. [DOI: 10.1016/j.ejps.2018.08.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
59 Di Ciaula A, Wang DQ, Molina-Molina E, Lunardi Baccetto R, Calamita G, Palmieri VO, Portincasa P. Bile Acids and Cancer: Direct and Environmental-Dependent Effects. Ann Hepatol 2017;16:s87-s105. [PMID: 29080344 DOI: 10.5604/01.3001.0010.5501] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
60 Kainuma M, Takada I, Makishima M, Sano K. Farnesoid X Receptor Activation Enhances Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells. Int J Mol Sci 2018;19:E1898. [PMID: 29958417 DOI: 10.3390/ijms19071898] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
61 Yu Q, Jiang Z, Zhang L. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. Pharmacol Ther 2018;190:81-90. [PMID: 29684468 DOI: 10.1016/j.pharmthera.2018.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
62 Uno S, Nebert DW, Makishima M. Cytochrome P450 1A1 (CYP1A1) protects against nonalcoholic fatty liver disease caused by Western diet containing benzo[a]pyrene in mice. Food Chem Toxicol 2018;113:73-82. [PMID: 29366871 DOI: 10.1016/j.fct.2018.01.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]